Squarepoint’s X4 Pharmaceuticals XFOR Stock Holding History

Squarepoint’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$313K	Buy	+67,078	New	+$275K	﹤0.01%	3774
2026 Q1	–	Sell	-12,518	Closed	-$50.1K	–	5081
2025 Q4	$50.1K	Buy	+12,518	New	+$45.5K	﹤0.01%	4131
2025 Q3	–	Sell	-38,982	Closed	-$74.1K	–	5090
2025 Q2	$74.1K	Buy	+38,982	New	+$160K	﹤0.01%	4235
2024 Q1	–	Sell	-2,159	Closed	-$54.3K	–	4688
2023 Q4	$54.3K	Buy	+2,159	New	+$52.5K	﹤0.01%	3838
2021 Q3	–	Sell	-688	Closed	-$134K	–	3490
2021 Q2	$134K	Sell	688 -15	-2%	-$3.77K	﹤0.01%	2959
2021 Q1	$181K	Buy	703 +131	+23%	+$34.4K	﹤0.01%	2736
2020 Q4	$110K	Buy	572 +171	+43%	+$33.6K	﹤0.01%	2704
2020 Q3	$81K	Sell	401 -309	-44%	-$74.1K	﹤0.01%	2319
2020 Q2	$199K	Buy	+710	New	+$194K	﹤0.01%	1825
2020 Q1	–	Sell	-456	Closed	-$146K	–	2603
2019 Q4	$146K	Buy	+456	New	+$164K	﹤0.01%	2289
2019 Q1	–	Sell	-193	Closed	-$81K	–	2476
2018 Q4	$81K	Buy	193 +104	+117%	+$39.7K	﹤0.01%	1817
2018 Q3	$26K	Buy	+89	New	+$37.7K	﹤0.01%	1938

Other funds holding XFOR

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

EAM

Empery Asset Management New York $86.5M AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Squarepoint's XFOR Position: Q2 2026 in Review

Squarepoint opened a new position in X4 Pharmaceuticals (XFOR) in Q2 2026: 67,078 shares worth $313K. The stake represents ﹤0.01% of the portfolio and ranks #3774 among its holdings. This is a return to the name: Squarepoint previously reported a position in XFOR as recently as Q4 2025.

Squarepoint first reported a position in XFOR in Q3 2018 and has held it in 12 quarters since. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

Squarepoint held 67,078 shares of X4 Pharmaceuticals worth $313K as of Q2 2026.
X4 Pharmaceuticals was a new Squarepoint position in Q2 2026.
X4 Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3774 holding.
Squarepoint first reported a position in X4 Pharmaceuticals in Q3 2018 and has held it in 12 quarters since.
89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.